Healthcare

Fortrea Adopts Limited-Duration Stockholder Rights Plan

Board Committed to Protecting Long-Term Value for All StockholdersDURHAM, N.C., June 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the…

6 months ago

Fortrea Adopts Limited-Duration Stockholder Rights Plan

Board Committed to Protecting Long-Term Value for All StockholdersDURHAM, N.C., June 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the…

6 months ago

Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp

Models provide highly relevant species-specific data, predict in vivo drug clearance/transport, and support preclinical analysis of cancer therapiesPITTSBURGH, June 12,…

6 months ago

Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp

Models provide highly relevant species-specific data, predict in vivo drug clearance/transport, and support preclinical analysis of cancer therapiesPITTSBURGH, June 12,…

6 months ago

Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp

Models provide highly relevant species-specific data, predict in vivo drug clearance/transport, and support preclinical analysis of cancer therapiesPITTSBURGH, June 12,…

6 months ago

Prenetics Announces First Quarter 2025 Financial Results, Raises FY2025 Outlook, & Crypto Strategy Announcement Soon

Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics)Raises full year revenue outlook to $80 - $100…

6 months ago

Prenetics Announces First Quarter 2025 Financial Results, Raises FY2025 Outlook, & Crypto Strategy Announcement Soon

Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics)Raises full year revenue outlook to $80 - $100…

6 months ago

Prenetics Announces First Quarter 2025 Financial Results, Raises FY2025 Outlook, & Crypto Strategy Announcement Soon

Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics)Raises full year revenue outlook to $80 - $100…

6 months ago

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

Key complex product approval in the Affordable Medicines segment this yearCommercial launch planned for third quarter of 2025 BRIDGEWATER, N.J.,…

6 months ago

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

Key complex product approval in the Affordable Medicines segment this yearCommercial launch planned for third quarter of 2025 BRIDGEWATER, N.J.,…

6 months ago